Clinical Trials Logo

T-lymphoblastic Lymphoma clinical trials

View clinical trials related to T-lymphoblastic Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06210750 Not yet recruiting - Clinical trials for T Acute Lymphoblastic Leukemia

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Start date: August 9, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests the safety and effectiveness of giving chemotherapy with or without venetoclax and/or navitoclax for the treatment of patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and navitoclax are in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. They may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy with or without venetoclax and/or navitoclax may be effective treatments for patients with newly diagnosed T-ALL or T-LBL.

NCT ID: NCT05068401 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Start date: March 2022
Phase: Phase 1
Study type: Interventional

This is a multi-phase, multi-center, single arm, prospective study designed to establish the safety and efficacy of human leukocyte antigen (HLA)-mismatched unrelated cryopreserved deceased donor bone marrow transplantation (BMT) with post-transplantation cyclophosphamide for patients with hematologic malignancies.